Skip to main content

Table 2 Group 3 results. Comparison between tumor volume, viscoelasticity |G*| and phase angle Y of tumors, NABT and the peripheral rim surrounding the tumor (“periphery”) at baseline and after 1st and 2nd treatment with B20 anti-VEGF-antibody. The p-values are derived from a one-way ANOVA followed by Bonferroni’s test for multiple comparisons. BL, baseline NABT, normal appearing brain tissue; SD, standard deviation

From: Magnetic Resonance Elastography reveals effects of anti-angiogenic glioblastoma treatment on tumor stiffness and captures progression in an orthotopic mouse model

Results one-way ANOVA

Results Bonferroni’s post-test

 

sum of squares

degree of freedom

mean squares

F

p-value

 

mean 1 (SD)

mean 2 (SD)

adjusted p-value

tumor volume

 

in mm3

in mm3

 

 treatment

202.2

2

101.1

2.74

0.1241

BL vs. after 1st B20 treatment

43.9 (6.4)

46.8 (14.0)

>  0.9

 individual

1559

4

389.7

10.56

0.0028

BL vs. after 2nd B20 treatment

43.9 (6.4)

52.7 (15.1)

0.15

     

After 1st vs. after 2nd B20 treatment

46.8 (14.0)

52.7 (15.1)

0.48

viscoelasticity |G*| tumor

 

in kPa

in kPa

 

 treatment

3.32

2

1.67

19.47

0.0008

BL vs. after 1st B20 treatment

5.8 (0.4)

5.0 (0.6)

0.0052

 individual

1.26

4

0.31

3.68

0.0551

BL vs. after 2nd B20 treatment

5.8 (0.4)

4.7 (0.2)

0.0010

     

After 1st vs. after 2nd B20 treatment

5.0 (0.6)

4.7 (0.2)

0.66

phase angle Y tumor

 

normalized

normalized

 

 treatment

0.002

2

0.001

6.03

0.0467

BL vs. after 1st B20 treatment

0.31 (0.01)

0.29 (0.02)

0.45

 individual

0.001

4

0.001

2.38

0.14

BL vs. after 2nd B20 treatment

0.31 (0.01)

0.28 (0.01)

0.04

     

After 1st vs. after 2nd B20 treatment

0.29 (0.02)

0.28 (0.01)

0.58

viscoelasticity |G*| NABT

 

in kPa

in kPa

 

 treatment

3.19

2

1.59

3.88

0.07

BL vs. after 1st B20 treatment

8.1 (0.6)

7.1 (0.6)

0.09

 individual

0.82

4

0.20

0.50

0.74

BL vs. after 2nd B20 treatment

8.1 (0.6)

7.3 (0.6)

0.21

     

After 1st vs. after 2nd B20 treatment

7.1 (0.6)

7.3 (0.6)

>  0.9

phase angle Y NABT

 

normalized

normalized

 

 treatment

0.003

2

0.002

7.28

0.02

BL vs. after 1st B20 treatment

0.35 (0.02)

0.39 (0.01)

0.02

 individual

0.003

4

0.001

3.56

0.06

BL vs. after 2nd B20 treatment

0.35 (0.02)

0.37 (0.03)

0.19

     

After 1st vs. after 2nd B20 treatment

0.39 (0.01)

0.37 (0.03)

0.41

viscoelasticity |G*| periphery

 

in kPa

in kPa

 

 treatment

1.00

2

0.51

3.06

0.10

BL vs. after 1st B20 treatment

6.6 (0.4)

6.0 (0.4)

0.13

 individual

1.88

4

0.47

2.87

0.10

BL vs. after 2nd B20 treatment

6.6 (0.4)

6.2 (0.7)

0.36

     

After 1st vs. after 2nd B20 treatment

6.0 (0.4)

6.2 (0.7)

>  0.9

phase angle Y NABT

 

normalized

normalized

 

 treatment

0.001

2

<  0.001

0.30

0.75

BL vs. after 1st B20 treatment

0.31 (0.01)

0.30 (0.02)

>  0.9

 individual

0.002

4

<  0.001

1.52

0.28

BL vs. after 2nd B20 treatment

0.31 (0.01)

0.31 (0.02)

>  0.9

     

After 1st vs. after 2nd B20 treatment

0.30 (0.02)

0.31 (0.02)

>  0.9

Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us